Lefort N, St-Amand E, Morasse S, Côté CH, Marette A. The ␣-subunit of AMPK is essential for submaximal contraction-mediated glucose transport in skeletal muscle in vitro. Am J Physiol Endocrinol Metab 295: E1447-E1454, 2008. First published September 23, 2008 doi:10.1152/ajpendo.90362.2008.-AMP-activated protein kinase (AMPK) is a key signaling protein in the regulation of skeletal muscle glucose uptake, but its role in mediating contraction-induced glucose transport is still debated. The effect of contraction on glucose transport is impaired in EDL muscle of transgenic mice expressing a kinase-dead, dominant negative form of the AMPK␣ 2 subunit (KD-AMPK␣2 mice). However, maximal force production is reduced in this muscle, raising the possibility that the defect in glucose transport was due to a secondary decrease in force production and not impaired AMPK␣ 2 activity. Generation of force-frequency curves revealed that muscle force production is matched between wild-type (WT) and KD-AMPK␣2 mice at frequencies Յ50 Hz. Moreover, AMPK activation is already maximal at 50 Hz in muscles of WT mice. When EDL muscles from WT mice were stimulated at a frequency of 50 Hz for 2 min (200-ms train, 1/s, 30 volts), contraction caused an ϳ3.5-fold activation of AMPK␣2 activity and an ϳ2-fold stimulation of glucose uptake. Conversely, whereas force production was similar in EDL of KD-AMPK␣2 animals, no effect of contraction was observed on AMPK␣2 activity, and glucose uptake stimulation was reduced by 50% (P Ͻ 0.01) As expected, 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranosyl 5Ј-monophosphate (AICAR) caused a 2.3-fold stimulation of AMPK␣ 2 activity and a 1.7-fold increase in glucose uptake in EDL from WT mice, whereas no effect was detected in muscle from KD-AMPK␣ 2 mice. These data demonstrate that AMPK activation is essential for both AICAR and submaximal contractioninduced glucose transport in skeletal muscle but that AMPK-independent mechanisms are also involved. adenosine 5Ј-monophosphate-activated protein kinase 5Ј-AMP-ACTIVATED PROTEIN KINASE (AMPK) is a member of a metabolite-sensing protein kinase family that responds to modulations in cellular energy levels (6, 14). When AMPK "senses" decreased energy stores, it acts to switch off ATPconsuming pathways and switch on alternative pathways for ATP regeneration. AMPK is a ubiquitous heterotrimer comprised of a catalytic ␣-and regulatory ␤-and ␥-subunits. It is thought to be a key actor in the alternative, non-insulinmediated pathways leading to glucose uptake in skeletal muscle (13). Because AMPK is potently activated by muscular contraction, it is also believed to represent a key signaling molecule for exercise-induced glucose transport (15, 28, 29, 35, 38) . In rats, exercise predominantly increases the activity of the ␣ 2 -subunit of AMPK while tetanic contractions ex vivo increase both the ␣ 1 and ␣ 2 AMPK subunits (26). Exercise performed at 65-70% V O 2max preferentially stimulates AMPK␣ 2 in human muscle, whereas activation of AMPK␣ 1 at this intensity is still controversial (4, 7, 39). In type 2 diabetic patients, exercise at 70% V O 2max stimulates AMPK␣ 2 activity to an extent similar to that observed in healthy subjects (25), making AMPK an attractive target for glucose-lowering pharmacological therapies.
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Transgenic models have proven essential in elucidating the role of AMPK␣ 2 in the alternative glucose transport pathway. Mu et al. (24) first showed that muscle-specific expression of a dominant inhibitory mutant of AMPK in transgenic mouse (KD-AMPK␣ 2 ) reduced contraction-induced glucose uptake by 30 -40%, whereas it fully abrogated the stimulatory effect of 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranosyl 5Ј-monophosphate (AICAR, a pharmacological activator of AMPK) or hypoxia on glucose transport. Knockout (KO) mouse models for individual AMPK␣ subunits were also generated. Whereas AMPK␣ 1 KO mice exhibited normal glucose homeostasis, mice lacking the AMPK␣ 2 showed impaired insulin secretion and in vivo insulin resistance (36, 37) . However, AMPK␣ 2 KO mice also exhibited increased adrenergic tone, which could explain both decreased insulin secretion and insulin resistance. Surprisingly, isolated muscles from AMPK␣ 2 KO mice failed to respond to AICAR but exhibited normal response to contraction-induced glucose uptake (20) . However, this is likely explained by a compensatory increase in expression and activity of the AMPK␣ 1 subunit. This compensatory response of the AMPK␣ 1 subunit was not observed in muscle-specific expression of a dominant inhibitory mutant of AMPK␣ 2 (24) . Interestingly, AMPK␥ 3 KO mice also display impaired AICAR-but not contraction-induced glucose uptake (2) . In this case, no compensatory increases in other ␥-or ␣-subunits were observed. Thus there is still some debate as to the exact role of AMPK in contraction-or exercise-induced glucose uptake in skeletal muscle.
A recent report suggests that contraction-mediated glucose transport is fully independent of AMPK␣ 2 , since it is not ablated in a second murine model expressing an inactive form of AMPK␣ 2 in skeletal muscle (␣ 2 i TG) (12) . This conclusion relies on the premise that, when force generation was matched between muscles of ␣ 2 i TG mice and their wild-type (WT) littermates, no deficit in contraction-induced glucose transport was observed. To match force production between WT and ␣ 2 i TG mice, Fujii et al. (12) opted to use a nonsupramaximal stimulation voltage (8.4 -21 volts) in the WT group compared with a supramaximal voltage (i.e., Ͼ30 volts) to stimulate ␣ 2 i TG muscles. However, this strategy has the inherent limitation of leading to differential recruitment in muscle fibers even though force production is matched between the genotypes. In the present study, a contraction stimulation protocol was designed to match force production between WT and KD-AMPK␣ 2 mice without compromising the voltage stimulation parameters in the WT mice and resulting in comparable fiber recruitment in both groups. This allowed us to investigate the role of AMPK in contraction-mediated glucose transport under conditions of similar fiber recruitment and muscle force responses, and thus test the hypothesis that AMPK is essential for contraction-induced glucose transport. When force development between KD-AMPK␣ 2 and WT extensor digitorum longus (EDL) muscles is matched, while using identical stimulation voltage and contraction protocols, glucose transport is diminished by one-half in EDL of KD-AMPK␣ 2 mice. Our data are thus consistent with a major role for AMPK in contraction-induced glucose transport.
EXPERIMENTAL PROCEDURES

Materials
AICAR was purchased from Toronto Research Chemicals (Toronto, Canada). [␥-
32 P]ATP, protein A-and G-Sepharose, and antimouse or antirabbit immunoglobulin G conjugated to horseradish peroxidase were purchased from Amersham Pharmacia Biotech (Baie d'Urfé, Canada). SAMS peptide was synthesized at the Eastern Quebec Proteomics Center at the Centre Hospitalier de l'Université Laval (CHUL) Research Center. Protein A/G PLUS-Agarose and anti-AMPK␣ 2 (C-20) were from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibodies used for immunoblotting [antiphospho-AMPK␣ 1/␣2 (pThr 172 ), anti-phospho-acetyl-CoA carboxylase (ACC) recognizing both ␣-and ␤-isoforms (pSer 79 ), anti-AMPK␣1 and anti-AMPK␣2 antibodies] were from Cell Signaling (Beverly, MA), and anti-c-myc (9E10) was purchased from Santa Cruz Biotechnology. All common chemicals were from Sigma and of the highest analytical grade.
Animals
All animal handling and treatments were approved and followed the guidelines set by Laval University Hospital Research Center Animal Care and Handling Committee. Mice were housed 2-5 per cage under a 12:12-h light-dark cycle in animal quarters at 22°C and allowed unlimited access to standard rodent food and water. WT and KD-AMPK␣ 2 mice (20 -25 g) were generated by an established colony at the CHUL Research Center, from original breeders generously provided by Dr. Morris Birnbaum (University of Pennsylvania). Food was withdrawn 15-18 h before experiments. Mice were anesthetized (50 mg/kg pentobarbital sodium ip) and were given the analgesic buprenorphine (0.1 mg/kg ip). EDL muscles were carefully dissected and either mounted vertically between two platinum electrodes for contraction studies or on a plastic support for AICAR treatments.
In Vitro Contraction Studies
EDLs were incubated in vitro and allowed to equilibrate for 15 min in 29°C oxygenated (95% O 2-5% CO2) Krebs buffer (in mM: 137 NaCl, 5 KCl, 1 MgSO4, 1 NaH2PO4, 2 CaCl2, 24 NaHCO3, 8 glucose, and 32 mannitol), at which time the optimal length (the muscle length which allows maximal twitch tension) was determined using five twitches. Muscles were incubated at this length for an additional 30 min. The force produced was visualized and analyzed on a digital oscilloscope (Hewlett-Packard) throughout the contraction protocol. A force-frequency curve was obtained on a set of muscles not used for glucose transport studies by using supramaximal voltage (30 -35 volts) and 200-ms train stimulations at frequencies ranging between 10 and 300 Hz with 2 min rest in between each contraction. The contraction protocol used for the contraction-stimulated glucose uptake (30 V, 50 Hz, 200-ms train, 1/s), which is near physiological conditions (42) , was performed during the last 2 min of the 30-min incubation. For immunoblotting studies and kinase activity assays, EDLs were frozen in liquid nitrogen immediately at the end of the protocol and stored at Ϫ80°C until processed.
AICAR treatment. EDLs were allowed to recover from the surgery for 30 min in oxygenated Krebs buffer supplemented with 8 mM glucose and 32 mM mannitol. EDLs were then incubated for 30 min in 2 mM AICAR in Krebs buffer in which the osmolarity was reduced to account for the contribution of AICAR (8 mM glucose and 30 mM mannitol). AICAR stock solution was prepared in Krebs buffer lacking glucose and mannitol, and the same volume of this buffer was added to basal muscles. Immediately after the protocol, EDLs underwent glucose transport measurement or were frozen in liquid nitrogen and stored at Ϫ80°C until processing.
In Vitro Glucose Transport Measures
Following the appropriate treatments (i.e., contraction or AICAR), EDLs were mounted on a plastic support if not previously done. Extracellular glucose was removed during a 10-min wash in Krebs buffer with 40 mM mannitol. Glucose transport was then measured via the incorporation of radiolabeled 2-[1,2 3 H(N)]deoxyglucose (DG) for 20 min, as previously described (21) . In brief, the muscles were incubated in 4 ml of Krebs buffer containing 8 mM 2-[ 3 H]DG (1.125 Ci/ml), 32 mM [
14 C]mannitol (0.15 Ci/ml), 2 mM sodium pyruvate, and 0.1% BSA at 29°C. Muscles were quickly dried, frozen in liquid nitrogen, and kept at Ϫ80°C. 2-[ 3 H]DG incorporation was determined by adding 1 ml of H2O to the muscles, incubating in boiling water for 10 min, and centrifuging at 10,000 g for 10 min. Aliquots of the supernatant and the radioactive incubation media were read using a Liquid Scintillation Analyzer (Tri-Carb 2800TR; PerkinElmer) for quantification of 3 H and 14 C. Results were expressed as micromoles glucose per gram per hour.
Kinase Assays AMPK activity. EDLs were ground to a powder and resuspended in lysis buffer [30 mM HEPES, pH 7.4, 2.5 mM EGTA, 3 mM EDTA, 70 mM KCl, 0.1% Nonidet P-40 (NP-40), 20 mM ␤-glycerophosphate, 20 mM NaF, 2 mM sodium tetrapyrophosphate, 1 mM Na3VO4, 200 M phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1:1,000 protease inhibitor cocktail (Sigma)]. Insoluble material was removed by centrifugation at 10,000 g for 10 min. Protein concentration was determined using the DC Assay (Bio-Rad Laboratories, Richmond, CA). Total protein lysate (200 g) was added to protein A/G-Sepharose coupled to anti-AMPK␣ 2 (2 g) or anti-AMPK␣1 (1 g) antibodies. After an overnight incubation, beads with immunocomplexes were washed extensively as follows: four times with 500 l of lysis buffer with 500 mM NaCl and two times with 500 l of reaction buffer (40 mM HEPES, pH 7.4, 80 mM NaCl, 5 mM MgCl 2, 1 mM dithiothreitol). Immunocomplexes were incubated in the presence of 50 l of reaction mix (200 M SAMS peptide, 100 M ATP, 240 M AMP, and 1 Ci [␥-
32 P]ATP, completed with reaction buffer) for 10 min at 37°C at 850 revolutions/min. Reaction mix (30 l) was blotted on P81 filter paper (Whatman International). Filter papers were washed 5 ϫ 20 min with 1% phosphoric acid to remove excess radioactivity not bound to the peptide. Remaining radioactivity on filter papers was quantified using a Liquid Scintillation Analyzer (Tri-Carb 2800 TR; Perkin-Elmer).
Western Blotting
Muscle protein lysate (50 g) was resolved by 7.5% SDS-PAGE, transferred to a polyvinylidene difluoride membrane, and analyzed by Western blot. Blots were blocked with 5% nonfat dry milk in 10 mM Tris, pH 7.5, 150 mM NaCl, 0.04% Igepal, and 0.02% NP-40, incubated with primary antibody overnight at 4°C (in 5% nonfat milk or 1-3% BSA), and then incubated with a secondary horseradishconjugated antibody for 1 h at room temperature. Immunoreactive bands were visualized by enhanced chemiluminescence (Immubilon Western; Millipore) and quantified by ImageQuant TL software. Relevant primary antibodies used were as follows: anti-phospho-AMPK␣, (1:1,000 dilution), anti-phospho-ACC (1:1,000 dilution), anti-c-myc (1:500 dilution), anti-AMPK␣ 1 (1:1,000), and anti-AMPK␣2 (1:1,000).
Data Analysis
All results are presented as means Ϯ SE. Statistical analysis of results was performed either by one-or two-way analysis of variance, and the assumptions of these models were systematically tested each time. Differences were considered to be statistically significant at P Ͻ 0.05.
RESULTS
Lack of AMPK␣ Activation and Glucose Transport Stimulation by AICAR in EDL from KD-AMPK␣ 2 Mice
As shown previously (24) , the mutated form of AMPK␣ 2 is tagged with a c-myc epitope that contributes to the slower electrophoretic mobility of this isoform on SDS-PAGE (Fig. 1A) . As expected, the endogenous ␣ 2 -subunit was fully replaced by the KD-dominant inhibitory mutant in the KD-AMPK␣ 2 mice. The c-myc epitope was solely expressed in muscles, as expected from its targeted expression in this tissue. Analysis of EDL muscles from several animals also revealed that the forced expression of the KD-dominant inhibitory mutant of AMPK␣ 2 also reduced the expression of the AMPK␣ 1 subunit by 66% (relative density units of WT: 0.67 Ϯ 0.16 vs. KD: 0.23 Ϯ 0.17, means Ϯ SE, P Ͻ 0.05). This is consistent with the observations of Mu et al. (24) who reported that the forced overexpression of the KD-AMPK␣ 2 leads to displacement of the endogenous ␣ 1 /␣ 2 -subunits from the heterotrimer followed by degradation of the free ␣-subunits.
We first assessed the effect of the AMPK pharmacological activator AICAR on EDL muscle of WT and KD-AMPK␣ 2 mice. AICAR induced the phosphorylation of AMPK␣ Thr172 (Fig. 1 , B and C) and its downstream target ACC Ser79 (Fig. 1, B and D) , but these effects were markedly reduced in muscles from KD-AMPK␣ 2 mice. The elevated basal phosphorylation of AMPK␣ in muscle of KD-AMPK␣ 2 mice has been reported previously (24) and may be considered a compensatory mechanism attempting to increase the activity of AMPK under fasting conditions. Direct measurements of AMPK kinase activity confirmed that expression of the kinase-dead form of AMPK␣ functions as a dominant inhibitory protein in muscle, blunting the AICAR-induced activation of both the ␣ 1 and ␣ 2 AMPK isoforms (Fig. 1E) . Incubation of WT EDL muscles with 2 mM AICAR led to an ϳ1.7-fold increase in glucose transport (P Ͻ 0.01), but AICAR failed to increase glucose transport in EDL of KD-AMPK␣ 2 mice (Fig. 1F) . These experiments confirm that the AMPK pathway is blunted in muscle of the KD-AMPK␣ 2 mouse and thus makes it an appropriate model for the study of AMPK-dependent processes in skeletal muscle.
Effects of different stimulation frequencies on muscle force and AMPK activation. To test the role of AMPK in contractioninduced glucose transport, it is imperative that the force produced by the WT muscle during electrical stimulation is matched to that of the KD-AMPK␣ 2 muscle. As shown in Fig. 2A , EDL muscles from WT mice have a significantly higher maximal absolute tetanic force compared with muscles of KD-AMPK␣ 2 mice. The deficit in force generation of the EDL from KD-AMPK␣ 2 mice only became significant in the upper end of the force-frequency curve. At frequencies Յ50 Hz, absolute force generation of KD-AMPK␣ 2 EDL was similar to that of WT EDL (Fig. 2A) . When muscles were electrically stimulated in vitro at 50 Hz, no significant difference was observed in the force generation or muscle fatigability over a 2-min period (area under curve: KD-AMPK␣ 2 : 94.4 Ϯ 7.2 vs. WT: 107.0 Ϯ 7.4, not significant; Fig.  2B ). Furthermore, we found that AMPK␣ Thr172 phosphorylation is already maximally induced at 50 Hz (Fig. 3) , indicating that this stimulation frequency is relevant to investigate the role of AMPK signaling in glucose uptake stimulation by contraction. Therefore, a 2-min 50-Hz electrical stimulation protocol was employed to study the contribution of AMPK in contraction-mediated glucose transport under matched force production.
Lack of AMPK␣ Activity Reduces Contraction-Induced Glucose Transport in EDL Muscles from KD-AMPK␣ 2 Mice
Phosphorylation of both AMPK Thr172 and ACC Ser79 was increased following submaximal contraction of WT mouse muscles at 50 Hz, whereas these responses were markedly blunted in EDL of KD-AMPK␣ 2 mice (Fig. 4, A-C ). An ϳ3.5-fold stimulation of AMPK␣ 2 activity was observed in electrically stimulated EDL muscles from WT mice, whereas contraction failed to increase AMPK␣ 2 activity in EDL of KD-AMPK␣ 2 animals (Fig. 4D) . Contraction also enhanced AMPK␣ 1 activity in WT muscle, but this effect was also abrogated in the KD-AMPK␣ 2 mice. We next triggered contraction of EDL muscles from both genotypes (50 Hz, 200-ms stimulation, 1/s, supramaximal voltage) and measured glucose uptake stimulation. After 2 min, glucose transport was stimulated 2.1-fold over basal in WT EDL muscles, whereas it was only stimulated 1.6-fold in muscles of KD-AMPK␣ 2 mice (Fig. 4E) . Thus glucose transport stimulation by contraction was reduced by 50% (P Ͻ 0.01 vs. WT muscles) in KD-AMPK␣ 2 muscles when compared with WT mice.
Discussion
Early studies showed that exercise (29) and electrically stimulated contractions (15, 28, 35, 38) increase the activity of AMPK in muscle. Moreover, several studies have shown that AICAR stimulates glucose transport in fast-twitch muscles and that its effect is not additive to that of contraction (3, 15, 23, 26) . Further genetic evidence for a role of AMPK in contraction-induced glucose uptake came from the work of Mu et al. (24) , who showed that expression of a dominant inhibitory mutant of AMPK in KD-AMPK␣ 2 muscle reduced contraction-induced glucose uptake by 30 -40%, whereas it fully abrogated the stimulatory effect of AICAR or hypoxia on glucose transport. Using another mouse model expressing an inactive form of AMPK␣ 2 in muscle, Fujii et al. (12) recently suggested that the stimulatory effect of contraction on glucose transport is fully independent of AMPK␣ 2 . This is based on the finding that, when force generation was matched between muscles of ␣ 2 i TG mice and their WT littermates, no deficit in contraction-induced glucose transport was observed. The need to match force production is related to the fact that mouse models lacking an active AMPK␣ 2 have a reduced capacity for maximal force production, a finding we have confirmed in KD-AMPK␣ 2 mice (see Fig. 2 ). However, the conclusion of Fujii et al. (12) relies on the premise that contraction-mediated glucose transport is proportional to force development (1, 17), but this is in fact a matter of debate, since early and more recent studies indicate that work load plays little, if any, role in contraction-mediated glucose transport (16, 33) . Of more concern is that Fujii and colleagues opted to use a nonsupramaximal voltage (8.4 -21 V) in the WT group to match force production to the level of the ␣ 2 i TG animals that were stimulated with a supramaximal voltage (i.e., Ͼ30 V). However, during electrical stimulation of isolated muscles ex vivo and particularly in the context of measuring glucose uptake, it is imperative that the voltage remains supramaximal to ensure activation of all (especially the deepest) muscle fibers (9) . Thus the option of reducing the stimulation voltage in the WT mice would inevitably lead to a lesser recruitment of the deepest muscle fibers, even though the work load was equal to that of ␣ 2 i TG muscle.
To circumvent these limitations, we designed a contraction stimulation protocol to match force production between WT and KD-AMPK␣ 2 Tg mice without compromising the voltage stimulation parameters in the WT mice, and thus fiber recruitment remained similar between groups. This was made possible by stimulating both WT and KD-AMPK␣ 2 EDL muscles at a lower frequency (50 Hz), where genotypic differences in absolute force production were no longer observed (Fig. 2) . This allowed us to investigate the role of AMPK in contraction-mediated glucose transport under conditions of equivalent electrical stimulation and muscle force responses. When muscle force development between genotypes is matched, using identical stimulation voltage and contraction protocols, glucose transport stimulation is diminished by one-half in EDL of KD-AMPK␣ 2 mice compared with WT littermates. Our data are therefore entirely consistent with a significant role for AMPK in submaximal contraction-induced glucose transport.
AMPK is currently believed to be primarily involved in glucose transport stimulation following high-intensity contraction or strenuous exercise. This is partly based on the observation that AMPK is absolutely required for hypoxia-induced glucose uptake (24, 32) , since oxygen availability may be reduced during strenuous exercise and intense muscle contraction. However, this dogma is now challenged by recent data showing that AMPK is activated by low-intensity contraction of muscles in vitro. Indeed, Toyoda et al. (34) recently reported that the ␣ 1 -subunit, but not the ␣ 2 -subunit, of AMPK is activated by a very low-intensity 2-min electrical stimulus (1-2 Hz) of epitrochlearis muscle (34) . Both isoforms were activated when the frequency was increased to Ͼ5 Hz or when the duration of the stimulus was Ͼ15 min. Furthermore, Jensen et al. (18) found that both the ␣ 1 -and ␣ 2 -subunits of AMPK can be activated in soleus and EDL muscles using a mild, low-work-load tetanic contraction protocol for 2-10 min where a high frequency (100 Hz) but a low train stimulation (1-s trains every 15 s) is applied. When this paper was under review, Jensen et al. (19) also reported that activation of the ␣ 1 -subunit of AMPK, but not the ␣ 2 -subunit, is necessary for twitch-stimulated (2 Hz, 2 min) glucose transport in soleus muscle. Our own protocol consisted of a middle-range frequency (50 Hz) combined with a more intense tetanic stimulation rate (0.2-s trains every s) for 2 min. Whatever the protocol used in these different studies, the general concept that can be derived from these data is that both the ␣ 1 -and ␣ 2 -subunits of AMPK can be activated by low-intensity contraction protocols (lower tetanic or reduced frequency), and our data in KD-AMPK␣ 2 mice further indicate that this activation is required for at least partial stimulation of glucose transport. These data also suggest that compensatory activation of the ␣ 1 AMPK subunit may have contributed to maintain contractioninduced glucose transport in muscle of AMPK␣ 2 KO mice (20) . However, in muscle of KD-AMPK␣ 2 mice, the forced expression of the AMPK␣ 2 dominant-negative inhibitory mutant also blunted the activation of the AMPK␣ 1 subunit by contraction (Fig. 4D) , suggesting that the nonabrogated portion of the contraction-induced glucose transport in EDL of KD-AMPK␣ 2 mice is not explained by a compensatory increased activation of the AMPK␣ 1 subunit.
Our finding that submaximal contraction-induced glucose uptake is only partially inhibited in muscle expressing a dominant-negative AMPK is in agreement with earlier work from Mu et al. (24) using a more intense contraction stimulus in the same model and with the growing concept that AMPK-independent mechanisms are also required for full stimulation of hexose uptake during contraction. AMPK-independent mechanisms are also essential for GLUT4 translocation to the muscle cell surface. Indeed, we previously found that AMPK activation with AICAR increases GLUT4 translocation to the plasma membrane but fails to induce recruitment of the transporter to T tubules (22) , which represent 60% of the total cell surface area in skeletal muscle fibers (8, 10) . Because we have reported that exercise and contraction stimulate GLUT4 translocation to both the plasma membrane and the T tubules (30, 31) , it is conceivable that contraction induces GLUT4 mobilization to the tubular elements through an AMPK-independent mechanism.
The nature of AMPK-independent pathways remains elusive. It was suggested that Ca 2ϩ /calmodulin-dependent protein kinase (CaMK) may represent one such pathway, since inhibitors (e.g., KN-93) of this kinase were reported to reduce contraction-induced glucose uptake during intense electrical stimulation of fast-and slow-twitch muscles without affecting AMPK activation (40, 41) . However, KN-93 was recently shown to inhibit AMPK activity and glucose uptake stimulation at the onset (i.e., 2 min) of mild tetanic contraction of EDL muscle, and further studies strongly suggested that low-inten- sity contraction rapidly activates CaMK kinase upstream of AMPK (18) . More recently, Raney and Turcotte (27) also showed that KN-93 inhibits contraction-induced AMPK activity, glucose uptake, and lipid uptake and oxidation in perfused rat hindlimb muscles. Thus it is unlikely that CaMK represents the AMPK-independent pathway that is stimulated by our contraction protocol, which is of short duration (2 min) and of submaximal intensity. Other molecules that have recently emerged as potential contraction-induced metabolic signals in skeletal muscle are neuregulins, a family of growth factors belonging to the epidermal growth factor family (5, 11). Canto and colleagues (5) recently reported that neuregulins are released by a Ca 2ϩ -dependent metalloproteinase activity that causes phosphorylation of the type I tyrosine kinase ErbB receptors. They further showed that recombinant active neuregulin-1 (HRG) increases glucose transport in myocytes and rat skeletal muscle. Both HRG and contraction-induced glucose uptake in isolated muscles are blunted by ErbB4 blockade. Importantly, HRG does not increase AMPK activity and AICAR-induced glucose transport is not affected by ErbB4 blockade, strongly suggesting that neuregulins mediate at least part of contraction-mediated glucose uptake through an AMPK-independent mechanism. It will be interesting to investigate in future studies whether the neuregulin/ErbB4 pathway is activated by submaximal contractions and contributes to glucose uptake stimulation in muscle of KD-AMPK␣ 2 mice.
In summary, the present study shows that, when force development is matched between electrically stimulated EDL muscles from WT and KD-AMPK␣ 2 mice, contraction-induced glucose transport is diminished by one-half in muscle of KD-AMPK␣ 2 mice. These results are thus consistent with a major role for AMPK in contraction-induced glucose transport in vitro. Our data also support the contribution of AMPKindependent mechanisms to the stimulation of glucose transport by contraction.
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